このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Celltrion Healthcare マネジメント

マネジメント基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

Hyoung Ki Kim

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	no data
CEOの所有権	n/a
経営陣の平均在職期間	データなし
取締役会の平均在任期間	less than a year

経営陣の近況

更新なし

Recent updates

CEO（最高経営責任者

Hyoung Ki Kim

no data

在職期間

Hyoung Ki Kim is CEO & Executive Director of Celltrion Healthcare Co., Ltd.

取締役

名称	ポジション	在職期間	報酬	所有権
Joon Serk Seo	Inside Co-Chairman of the Board	less than a year	データなし	データなし
Hyoung Ki Kim	CEO & Executive Director	no data	データなし	データなし
Jung-Jin Seo	Inside Co-Chairman of the BOD	less than a year	データなし	11.73% ₩ 1.4t
Eung Yeol Choi	Independent Director	no data	データなし	データなし
Woon Gap Jueng	Independent Director	no data	データなし	データなし
Hyeon Ju Ra	Independent Director	no data	データなし	データなし
Joong Jae Lee	Independent Director	no data	データなし	データなし
Won Kyung Choi	Independent Director	2.8yrs	データなし	データなし
Jong Mun Choi	Independent Director	less than a year	データなし	データなし

0.8yrs

平均在職期間

経験豊富なボード: A091990の取締役会は経験豊富ではない ( 0.8年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Celltrion Healthcare マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

Recent updates

Celltrion Healthcare Co., Ltd.(KOSDAQ:A091990) dropped from FTSE All-World Index (USD)

Third quarter 2023 earnings released: EPS: ₩281 (vs ₩853 in 3Q 2022)

Celltrion Healthcare Presents Phase III Data from the LIBERTY-CD and LIBERTY-UC Clinical Trials

Celltrion, Inc. agreed to acquire a 64.46% stake in Celltrion Healthcare Co., Ltd. (KOSDAQ:A091990) for KRW 6.7 billion

Consensus EPS estimates fall by 11%

Full year 2022 earnings: EPS misses analyst expectations

Investor sentiment improves as stock rises 15%

Upcoming dividend of ₩130 per share

Consensus forecasts updated

Consensus EPS estimates fall by 19%

European Commission Approves Celltrion Healthcare’s Vegzelma (CT-P16, biosimilar bevacizumab) for the Treatment of Multiple Types of Cancer

Price target increased to ₩83,571

Consensus forecasts updated

Price target increased to ₩75,167

Price target decreased to ₩69,333

Price target decreased to ₩78,311

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus forecasts updated

Celltrion Group Announces Positive Results for Its Cocktail Therapy Candidates Including Neutralisation Data Against Omicron Variant

Price target decreased to ₩99,889

Celltrion Accelerates Development of Nebulised Cocktail Therapy (CT-P63 in Combination with CT-P59) Using Its Antibody Platform to Tackle New Covid-19 Variants

Price target decreased to ₩109,900

Price target decreased to ₩127,200

Investor sentiment deteriorated over the past week

Celltrion Receives Approval from Korean Ministry of Food and Drug Safety for regdanvimab

Consensus EPS estimates fall to ₩1,997

Celltrion’S Monoclonal Antibody Treatment for COVID-19, Regdanvimab, Demonstrates Strong Neutralising Activity Against Delta Variant

Celltrion Healthcare Announces Positive Top-Line Results from Global Phase III Trial of Regdanvimab (CT-P59), an Anti-Covid-19 Monoclonal Antibody Treatment

Celltrion Healthcare Presents Positive One-Year Data for YuflymaTM (Ct-P17)

Consensus EPS estimates fall to ₩2,086

Celltrion Confirms Neutralising Potency Against Emerging SARS-CoV-2 Variants With Anti-COVID-19 Monoclonal Antibody Treatment regdanvimab (CT-P59)

Celltrion Healthcare Receives Positive Chmp Opinion for Subcutaneous Formulation of Infliximab, Remsima® Sc, for Direct Use of Subcutaneous Therapy Without Iv Loading in Adults with Rheumatoid Arthritis

New 90-day low: ₩120,700

Celltrion Healthcare Receives European Commission Approval for the First High Concentration, Low-Volume and Citrate-Free Biosimilar Adalimumab, YuflymaTM

Price target raised to ₩131,030

New 90-day high: ₩176,900

Celltrion Healthcare Receives EU CHMP Positive Opinion for Biosimilar Adalimumab, CT-P17

New 90-day high: ₩108,100

Celltrion Healthcare Presents Positive Top-Line Efficacy and Safety Results for CT-P17 in the Treatment of Rheumatoid Arthritis

New 90-day low: ₩84,700

Celltrion Initiates Post-Exposure Prophylaxis Clinical Trial of an Anti-COVID-19 Monoclonal Antibody Treatment Candidate, CT-P59

Celltrion Healthcare Announces Two New Data Sets Relating to the Use of the Subcutaneous Formulation of Infliximab, Remsima

New 90-day low: ₩94,200

Celltrion Receives Korean MFDS Approval to Initiate Phase Ii/Iii Pivotal Trial of an Anti-COVID-19 Monoclonal Antibody Treatment Candidate, CT-P59

CEO（最高経営責任者

在職期間

取締役

平均在職期間

マネジメント基準チェック /04